Dr. Reddy's Laboratories Limited — Important, 08-12-2025: Arrangements for strategic, technical, manufacturing, or marketing tie up

Dr. Reddy's partnered with Immutep SAS for exclusive rights to develop/commercialize Eftilagimod Alfa, an innovative cancer immunotherapy. This expands Dr. Reddy's oncology presence globally (ex-major markets), aiming to deliver new cancer treatments. Immutep gets $2 Cr upfront, up to $34.95 Cr milestones.